A crossflow filter includes a rigid cylindrical inner wall and a rigid cylindrical outer wall with an inelastic filter membrane positioned therebetween defining a retentate channel inside the filter membrane and a permeate channel outside the filter membrane. Further, the filter includes transition channels shaped and connected to the inner and outer walls to deliver a flow of fluid from an inlet port to the retentate channel and to capture flow flowing longitudinally along the cylindrical inner and outer walls from both the retentate and permeate channels to respective outlet ports.

A crossflow filter includes a rigid cylindrical inner wall and a rigid cylindrical outer wall with an inelastic filter membrane positioned therebetween defining a retentate channel inside the filter membrane and a permeate channel outside the filter membrane. Further, the filter includes transition channels shaped and connected to the inner and outer walls to deliver a flow of fluid from an inlet port to the retentate channel and to capture flow flowing longitudinally along the cylindrical inner and outer walls from both the retentate and permeate channels to respective outlet ports.

The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.

The invention relates to a method for manufacturing a hollow fiber membrane bundle from a plurality of polysulfone and PVP-based hollow fiber membranes which encompasses the providing of a spinning solution comprising a polysulfone-based material, in particular polysulfone, a vinylpyrrolidone-based polymer, in particular polyvinylpyrrolidone, an aprotic solvent, in particular dimethylacetamide, providing a coagulant liquid comprising water and an aprotic solvent, in particular dimethylacetamide, co-extruding the spinning solution and the coagulant liquid through a concentric annular spinneret into a hollow strand, whereby the cavity of the strand is filled with coagulant liquid, conducting the strand through a precipitation gap, introducing the strand into a precipitating bath comprised substantially of water so as to obtain a hollow fiber membrane, conducting the hollow fiber membranes through at least one rinsing bath and drying the hollow fiber membrane obtained, arranging the resulting hollow fiber membranes into a hollow fiber membrane bundle, and treating the hollow fiber membrane bundle with water vapor.

A microwave therapy apparatus and method for blood cancer treatment is disclosed. The microwave therapy apparatus for blood cancer treatment includes a plurality of porous anodic aluminum oxide (AAO) filters or a plurality of porous glass filters provided in a dialyzer of a hemodialysis apparatus; a nanoflower filter provided downstream of the plurality of porous anodic aluminum oxide (AAO) filters or the plurality of porous glass filters in the blood tube; and an RF absorber provided downstream of the nanoflower filter to attract cancer cells thereto by generating a frequency of a predetermined band, wherein the blood, from which the cancer cells have been removed by an RF frequency and which includes normal blood cells that passed through the nanoflower filter, is circulated and supplied to a blood tube connected to a vein of the body of the blood cancer patient.

A hollow fiber membrane module includes: a first hollow fiber membrane whose sieving coefficient for dextran having a molecular weight of not less than 300 kDa nor more than 1000 kDa is not less than 0.12 nor more than 0.28, wherein the first hollow fiber membrane adsorbs endotoxins.

A hollow fiber membrane module includes: a first hollow fiber membrane whose sieving coefficient for dextran having a molecular weight of not less than 300 kDa nor more than 1000 kDa is not less than 0.12 nor more than 0.28, wherein the first hollow fiber membrane adsorbs endotoxins.

A machine comprising a load-bearing body intended to receive a circuit for the extracorporeal circulation of a biological liquid, where the circuit comprises at least one bag containing the biological liquid, at least one collection container of the biological liquid to be treated, at least one transit duct of the biological liquid connected to at least the bag and to the collection container; a pumping unit/device/component/etc. of the biological liquid crossing the transit duct; an irradiation unit/device/component/etc. by way of UVA rays of the collection container; and at least one containment box defining a containment volume intended to house the collection container and at least one safety chamber arranged below the containment volume and communicating therewith, to collect any possible spillage of the biological liquid from the collection container where the safety chamber has at least one bottom wall and two side walls at which it is hermetically sealed.

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the αI7I-I85cit peptide of amino acid sequence VDIDIKIX.sub.1SCX.sub.2GSCS (SEQ ID NO: 8) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue, —the α62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue.